constructed a mutational subtype of melanoma based on the BRAF mutation patterns of 2 FAM-related genes, ALDH1A1 and ALDH1A3; however, this CM subtype accounts for ALDH1A3 expression as only a prognostic marker for BRAF/MEK inhibitor treatment response in BRAF-mutant metastatic melanoma patients (50). The gene discussed is BRAF; the disease is metastatic melanoma.